IBT Receives an SBIR from NIAID to engineer an Ebola Antibody to Achieve broad Filovirus Protection
A major challenge in the fight against filovirus infections is the fact that the nature of epidemics cannot be predicted. Beside the Zaire strain of Ebolavirus other ebolaviruses such as Sudan virus, Bundibugyo virus as well as the more distant relative Marburg virus have caused highly lethal outbreaks. One of the primary goals of IBT is to develop broadly protective antibodies against filoviruses.
Under this SBTR, IBT will work with Visterra, Inc. (Cambridge, MA) and US Army Medical Research Institute of Infectious Diseases (USAMRIID) to engineer a broadly reactive monoclonal antibody that only neutralizes ebolavirus species to achieve neutralizing activity towards Marburg virus. This collaborative research is based on a unique set of macaque-derived monoclonal antibodies developed at IBT and an innovative technology developed by Visterra scientists that allows for computational redesign of antibodies to achieve broad reactivity. Through this collaboration, IBT and Visterra hope to develop the first antibody with protective activity against the most divergent filoviruses.